| Literature DB >> 36015362 |
Jitong Wang1, Jia Zeng2, Zhidan Liu3, Qin Zhou1, Xin Wang1, Fan Zhao1, Yu Zhang1, Jiamiao Wang4, Minchen Liu1, Ruofei Du1.
Abstract
Arthritis is a general term for various types of inflammatory joint diseases. The most common clinical conditions are mainly represented by rheumatoid arthritis and osteoarthritis, which affect more than 4% of people worldwide and seriously limit their mobility. Arthritis medication generally requires long-term application, while conventional administrations by oral delivery or injections may cause gastrointestinal side effects and are inconvenient for patients during long-term application. Emerging microneedle (MN) technology in recent years has created new avenues of transdermal delivery for arthritis drugs due to its advantages of painless skin perforation and efficient local delivery. This review summarizes various types of arthritis and current therapeutic agents. The current development of MNs in the delivery of arthritis drugs is highlighted, demonstrating their capabilities in achieving different drug release profiles through different self-enhancement methods or the incorporation of nanocarriers. Furthermore, the challenges of translating MNs from laboratory studies to the clinical practice and the marketplace are discussed. This promising technology provides a new approach to the current drug delivery paradigm in treating arthritis in transdermal delivery.Entities:
Keywords: arthritis; drug delivery; microneedle; transdermal route
Year: 2022 PMID: 36015362 PMCID: PMC9416616 DOI: 10.3390/pharmaceutics14081736
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525